Lenvatinib and Selpercatinib Successfully Treated RET Fusion Gene-Positive Papillary Thyroid Carcinoma Cardiac Metastases: a Case Report
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660185/
Cardiac metastasis from thyroid cancer is rare and has an extremely poor prognosis. Although some patients who undergo heart surgery survive, the therapeutic effectiveness of systemic therapy is limited.
This is the first case of cardiac metastasis of papillary thyroid carcinoma treated successfully with systemic therapy.
Relationship Between Driver Gene Mutations and Clinical Pathological Characteristics in Older Lung Adenocarcinoma
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646490/
Lung adenocarcinoma (LUAD) is the most common newly diagnosed malignant tumor in older people. As older patients age, organ function decreases, leading to increased adverse reactions to treatment.
In addition to common EGFR activation mutations, targets such as ALK rearrangement, ROS1 rearrangement, RET rearrangement, BRAF V600E, MET exon 14 skip mutation, KRAS G12C, and others have been gradually approved for targeted drug application in advanced non–small-cell lung cancer.
Precision medicine in thyroid cancer involves the integration of omics sciences with clinical data to develop personalized treatment plans for patients.
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer
Source : https://pubmed.ncbi.nlm.nih.gov/37870969/
Selpercatinib treatment resulted in superior progression-free survival and treatment failure-free survival as compared with cabozantinib or vandetanib in patients with RET -mutant medullary thyroid cancer.
Selpercatinib treatment resulted in superior PFS and treatment failure-free survival versus cabozantinib or vandetanib in patients with RET-mutant medullary thyroid cancer.
Pralsetinib in Patients With RET Fusion-Positive Non-Small Cell Lung Cancer: a Plain Language Summary of the ARROW Study
Source : https://pubmed.ncbi.nlm.nih.gov/37916501/
Overall, the ARROW study showed that pralsetinib was effective in shrinking tumours in patients with RET fusion+ NSCLC regardless of previous treatment history.
Overall, the ARROW study showed that pralsetinib was effective in shrinking tumours in patients with RET fusion+ NSCLC regardless of previous treatment history.